BioSpace News Archive

HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced an agreement with Biodesix, Inc. (Nasdaq: BDSX) to further the development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic in future registrational trials in breast cancer for Imprime PGG programs.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) (“Astellas”) to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology platform.

Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Kim A. Keck has been appointed to its Board of Directors,

Willow Biosciences Inc. (" Willow " or the " Company ") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it is undertaking two initiatives to help our customers evaluate and better understand cannabigerol (" CBG "), our first commercial cannabinoid slated for production in Q1 2021. Willow ha

KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced that it has entered into a broad strategic collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) to research, develop and commercialize novel immune-based therapies for cancer.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has received a positive response from the U.S. Food and Drug Administration (FDA) that the efficacy and safety data resulting from the company’s pivotal Phase 3 Marigold Study on the use of oral ganaxolone

The debut of a new U.S. based global biotechnology company, Vaxxinity, will take place at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, at 9:50 a.m. EST.

Glaukos Corporation (NYSE: GKOS),today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 24-month interim analysis of the ongoing 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (IND) protocol.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent for $80 million in cash.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the receipt of a $0.9 million payment as the second installment of $1.7 million in scheduled payments to Salarius under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT)